NCT00264875

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 220 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy

Conditions

• Peripheral Neuropathy
• HIV Infections

Interventions

Type	Name	Description
DRUG	pregabalin	75mg BID, titrated up to 300mg according to individual response and tolerability

Timeline

• Start date: 2006-02-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2005-12-13
• Last updated: 2021-01-22
• Results posted: 2009-03-23

Locations

37 sites across 2 countries: United States, Puerto Rico